Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis

Immunological Reviews

Volumn 174, Issue , 2000, Pages 250-259

  Czaja, Albert J ^a   Donaldson, Peter T ^b  

^a MAYO CLINIC   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; AUTOANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; HLA ANTIGEN; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYPEPTIDE;

ALLELE; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARGENTINA; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; EUROPE; FEMALE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOREACTIVITY; JAPAN; LIVER CELL DAMAGE; MEXICO; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T LYMPHOCYTE;

ADULT; ALLELES; AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ARGENTINA; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BRAZIL; CHILD; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 6; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EVOLUTION, MOLECULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS, AUTOIMMUNE; HLA-DR ANTIGENS; HUMANS; IMMUNOCONJUGATES; JAPAN; MALE; MEXICO; MODELS, IMMUNOLOGICAL; MOLECULAR MIMICRY; PROTEIN CONFORMATION; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034077771     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0528.2002.017401.x     Document Type: Review

References (102)

1. 1. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 1984;4:1-12.
2. 2. Johnson PJ, et al. Meeting report. International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
3. 3. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. Med Clin North Am 1996;80:973-994.
4. 4. Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 1998;18:271-279.
5. 5. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995;90:1206-1211.
6. 6. Homberg J-C, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7:1333-1339.
7. 7. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103:1290-1295.
8. 8. Czaja AJ. Autoimmune hepatitis: current therapeutic concepts. Clin Immunother 1994;1:413-429.
9. 9. Czaja AJ. Drug therapy in the management of type I autoimmune hepatitis. Drugs 1999;57:49-68.
10. 10. McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 1984;55:347-354.
11. 11. Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 1991;11:215-222.
12. 12. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996;41:1733-1740.
13. 13. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989;83:1066-1072.
14. 14. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-1378.
15. 15. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of the anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993;104:1762-1767.
16. 16. Loeper J, et al. Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993;104:203-216.
17. 17. Manns M, et al. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 1990;12:127-132.
18. 18. Lohr H, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991;84:297-302.
19. 19. Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategìes. Dig Dis Sci 1995;40:435-456.
20. 20. Czaja AJ. Autoantibodies. Baillieres Clin Gastroenterol 1995;9:723-744.
21. 21. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30:394-401.
22. 22. Tomer Y, Shoenfeld Y. The significance of natural autoantibodies. Immunol Invest 1988;17:389-424.
23. 23. Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol 1992;22:2989-2993.
24. 24. Choudhuri K, Gregorio GV, Mieli-Vergani G, Vergani D. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Hepatology 1998;28:1177-1181.
25. 25. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996;9:532-562.
26. 26. Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci 1998;43:2149-2155.
27. 27. Mackay IR, Morris PJ. Association of autoimmune active chronic hepatitis with HL-A1, 8. Lancet 1972;2:793-795.
28. 28. Page AR, Sharp HL, Greenberg LJ. Genetic analysis of patients with chronic active hepatitis. J Clin Invest 1975;56:530-535.
29. 29. Williams RM, et al. Increased frequency of HLA-DRW4 in chronic active hepatitis. Vox Sang 1978;35:366-369.
30. 30. Mackay IR, Tait BD. HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980;79:95-98.
31. 31. Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI. HLA determinants in chronic active liver disease: possible relation of HLA-Dw3 to prognosis. Tissue Antigens 1977;9:36-40.
32. 32. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991;13:701-706.
33. 33. Manabe K, et al. Human leukocyte antigen A1-B8-DR3-DQ2-DPB1 *0401 extended haplotype in autoimmune hepatitis. Hepatology 1993;18:1334-1337.
34. 34. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-1507.
35. 35. Doherty DG, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994;19:609-615.
36. 36. Strettell MDJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-2035.
37. 37. Strettell MDJ, Thomson LJ, Donaldson PT, Bunce M, O'Neill CM, Willams R. HLA-C genes and susceptibility to type 1 autoimmune hepatitis. Hepatology 1997;26:1023-1026.
38. 38. Donaldson PT, Manns MP. Immunogenetics of liver disease. In: Bircher J, Benhamou J-P, McIntyre N, Rizetto M, Rodes J, eds. Oxford textbook of clinical hepatology. Oxford: Oxford University Press; 1999. p. 173-188.
39. 39. Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990;12:1300-1304.
40. 40. Seki T, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992;103:1041-1047.
41. 41. Fainboim L, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRBI*1301) haplotype. Hum Immunol 1994;41:146-150.
42. 42. Marcos Y, et al. Two-locus involvement in the association of human leukocyte antigen with the extrahepatic manifestations of autoimmune chronic active hepatitis. Hepatology 1994;19:1371-1374.
43. 43. Vazquez-Garcia MN, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-990.
44. 44. Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Laudanna AA, Kalil J. Different HLA profiles confer susceptibility to autoimmune hepatitis type 1 and 2. Am J Gastroenterol 1998;93:1394-1395.
45. 45. Bittencourt PL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94:1906-1913.
46. 46. Gregorio GV, et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997;25:541-547.
47. 47. Farrant JM, et al. Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992;16:390-395.
48. 48. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA DR and DQ are not markers for rapid progression in primary sclerosing cholangitis. Gastroenterology 1995;108:870-878.
49. 49. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997;92:2197-2200.
50. 50. Czaja AJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25:317-323.
51. 51. Czaja AJ, Rakela J, Hay JE, Moore SB. Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1990;98:1587-1593.
52. 52. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15:215-221.
53. 53. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993;18:816-822.
54. 54. Donaldson PT, Doherty DG, Underhill JA, Williams R. Molecular genetics of autoimmune liver disease. Hepatology 1994;20:225-239.
55. 55. Nepom GT. A unified hypothesis for the complex genetics of HLA associations with IDDM. Diabetes 1990;39:1153-1157.
56. 56. Sheehy MJ. HLA and insulin-dependent diabetes: a protective perspective. Diabetes 1992;41:123-129.
57. 57. Brown JH, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-39.
58. 58. Schwartz RS. The new immunology - the end of immunosuppressive drug therapy? N Engl J Med 1999;340:1754-1756.
59. 59. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990;87:1233-1237.
60. 60. Pociot F, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:224-231.
61. 61. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997;158:1989-1993.
62. 62. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-450.
63. 63. Payami H, Khan MA, Grennan DM, Sanders PA, Dyer PA, Thomson G. Analysis of genetic interrelationship among HLA-associated diseases. Am J Hum Genet 1987;41:331-349.
64. 64. Price P, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999;167:257-274.
65. 65. Tilg H, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-274.
66. 66. Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-α in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 1995;20:23-27.
67. 67. Al-Wabel A, Al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol 1993;92:902-908.
68. 68. Lohr HF, Schaak JF, Gerken G, Fleischer B, Dienes H-P, Meyer zum Buschenfelde K-H. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994;14:161-166.
69. 69. Schlaak JF, Lohr H, Gallati H, Meyer zum Buschenfelde K-H, Fleischer B. Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin Exp Immunol 1993;94:168-173.
70. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-38.
71. 71. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996;9:532-562.
72. 72. Peters M. Actions of cylokines on the immune response and viral interactions: an overview. Hepatology 1996;23:909-916.
73. 73. Czaja AJ, Sievers C, Zein NN. Nature and behavior of immunoregulatory cytokines in type 1 autoimmune hepatitis. Gastroenterology 1999;116:A1199.
74. 74. Swain SL. Lymphokines and the immune response: the central role of interleukin-2. Curr Opin Immunol 1991;3:304-310.
75. 75. Vento S, Nouri-Aria KT, Eddleston ALWF. Immune mechanisms in autoimmune chronic active hepatitis. Scand J Gastroenterol 1985;20 (Suppl 114):91-103.
76. 76. Cookson S, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999;30:851-856.
77. 77. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;177:645-652.
78. 78. Wilson AG, Symons JA, McDowell TL, di Giovine FS, Duff GW. Effects of a tumor necrosis factor (TNF-α) promoter base transition on transcriptional activity. Br J Rheumatol 1994;33:89-92.
79. 79. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associtaed with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-560.
80. 80. Pociot F, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:224-231.
81. 81. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997;158:1989-1993.
82. 82. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-450.
83. 83. Marron MP, et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA-4 polymorphisms in multiple ethnic groups. Hum Mol Gen 1997;6:1275-1282.
84. 84. Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 gene polymorphism confers susceptibility to type 1 autoimmune hepatitis. Hepatology 1999;30:495A.
85. 85. Agarwal K, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. Hepatology 1998;28:404A.
86. 86. Saarinen A, Broome U, Liger A, Olsson R, Hulcrantz R, Olerup O. CTLA-4 gene polymorphism associated with primary sclerosing cholangitis (PSC). J Hepatol 1998;28 (Suppl):124.
87. 87. Donner H, et al. CTLA-4 alanine-17 confers genetic susceptiblity to Graves' Disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997;81:143-146.
88. 88. Nistico L, et al. The CTLA-4 region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Hum Mol Gen 1996;5:1075-1080.
89. 89. Manabe K, et al. T-cell receptor constant β germline polymorphisms and susceptibility to autoimmune hepatitis. Gastroenterology 1994;106:1321-1325.
90. 90. Arenz M, Meyer zum Buschenfelde K-H, Lohr HF. Limited T cell receptor Vβ-chain repertoire of liver-infiltrating T cells in autoimmune hepatitis. J Hepatol 1998;28:70-77.
91. 91. Whittingham S, Mathews JD, Schanfield MS, Tait BD, Mackay IR. Interaction of HLA and Gm in autoimmune chronic active hepatitis. Clin Exp Immunol 1981;43:80-86.
92. 92. Krawitt EL, et al. Immunogenetic studies of autoimmune chronic active hepatitis: HLA, immunoglobulin allotypes and autoantibodies. Hepatology 1987;7:1305-1310.
93. 93. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995;108:157-164.
94. 94. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig Dis Sci 1995;40:2098-2106.
95. 95. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997;26:459-466.
96. 96. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996;24:52-59.
97. 97. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 1993;18:342-352.
98. 98. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41:305-314.
99. 99. Czaja AJ. Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am 1994;23:547-566.
100. 100. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-1832.
101. 101. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-598.
102. 102. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-365.